Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

– Patient enrollment exceeding expectations –

– 14 U.S. sites actively enrolling; 10 U.S. sites added since last update –

– Anticipate completing NEXICART-2 clinical trial ahead of schedule –

Read more at globenewswire.com